References
- Bowlin SJ, Xia F, Wang W, et al. Twelve-month frequency of drug-metabolizing enzyme and transporter-based drug-drug interaction potential in patients receiving oral enzyme-targeted kinase inhibitor antineoplastic agents. Mayo Clin Proc. [Internet]. 2013;88:139–148.
- Döhner H, Weisdorf DJ, Bloomfield CD. Acute Myeloid Leukemia. Longo DL, editor. N Engl J Med Internet]. 2015;373:1136–1152. Available from. http://www.nejm.org/doi/10.1056/NEJMra1406184
- Megías-Vericat JE, Solana-Altabella A, Ballesta-López O, et al. Drug-drug interactions of newly approved small molecule inhibitors for acute myeloid leukemia. Ann Hematol. Internet]. 2020;99:1989–2007. Available from. https://link.springer.com/10.1007/s00277-020-04186-0
- Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. Internet]. 2009;339:b2700–b2700. Available from. https://www.bmj.com/lookup/doi/10.1136/bmj.b2700
- Bazarbachi A, Labopin M, Battipaglia G, et al. Sorafenib improves survival of FLT3 -mutated acute myeloid leukemia in relapse after allogeneic stem cell transplantation: a report of the EBMT acute leukemia working party. Haematologica. Internet]. 2019;104:e398–e401. Available from. http://www.haematologica.org/lookup/doi/10.3324/haematol.2018.211615
- Röllig C, Serve H, Noppeney R, et al. Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial. Leukemia Internet]. 2021;35:2517–2525. Available from.;.:https://www.nature.com/articles/s41375-021-01148-x
- Zirm E, Spies-Weisshart B, Heidel F, et al. Ponatinib may overcome resistance of FLT3-ITD harbouring additional point mutations, notably the previously refractory F691I mutation. Br J Haematol. Internet]. 2012;157:483–492. Available from. https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2012.09085.x
- Gozgit JM, Wong MJ, Wardwell S, et al. Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies. Mol Cancer Ther Internet]. 2011;10:1028–1035. Available from. https://aacrjournals.org/mct/article/10/6/1028/91144/Potent-Activity-of-Ponatinib-AP24534-in-Models-of
- Kipp D, Loo S, Perkins AC, et al. A phase-Ib/II clinical evaluation of ponatinib in combination with azacitidine in FLT3 -ITD and CBL -mutant acute myeloid leukemia (PON-AZA study). Blood Internet]. 2021;138:2350. Available from. https://ashpublications.org/blood/article/138/Supplement1/2350/478524/A-Phase-Ib-II-Clinical-Evaluation-of-Ponatinib-in
- Hu S, Mathijssen RHJ, de Bruijn P, et al. Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro–in vivo correlations. Br J Cancer Internet]. 2014;110:894–898. Available from. http://www.nature.com/articles/bjc2013811
- He H, Tran P, Gu H, et al. Midostaurin, a novel protein kinase inhibitor for the treatment of acute myelogenous leukemia: insights from human absorption, metabolism, and excretion studies of a BDDCS II drug. Drug Metab Dispos. Internet]. 2017;45:540–555. Available from. http://dmd.aspetjournals.org/lookup/doi/10.1124/dmd.116.072744
- CENTER FOR DRUG EVALUATION AND RESEARCH. Clinical pharmacology and biopharmaceutics review (207997Orig1s000, 207997Orig2s000). midostaurin (rydapt). Food Drug Adm. Internet]. 2017; Available from. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf
- Comitte for Medicinal Products from Human Use (CHMP). European Public Assessment Resport (EPAR) - midostaurin (rydapt) EMEA/H/C/004095/0000. 2017;44. Available from: https://www.ema.europa.eu/en/documents/assessment-report/rydapt-epar-public-assessment-report_en.pdf.
- U.S. Food and Drug Administration (FDA). Novartis pharmaceuticals corporation (2017) rydapt (midostaurin): US prescribing information. 2017; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207997s000lbl.pdf.
- Hsiao S-H, Lusvarghi S, Huang Y-H, et al. The FLT3 inhibitor midostaurin selectively resensitizes ABCB1-overexpressing multidrug-resistant cancer cells to conventional chemotherapeutic agents. Cancer Lett. 2019;445:34–44. Internet
- Filppula AM, Mustonen TM, Backman JT. Vitro screening of six protein kinase inhibitors for time-dependent inhibition of CYP2C8 and CYP3A4: possible implications with regard to drug-drug interactions. Basic Clin Pharmacol ToxicolInternet]. 2018;123:739–748.
- Dutreix C, Munarini F, Lorenzo S, et al. Investigation into CYP3A4-mediated drug–drug interactions on midostaurin in healthy volunteers. Cancer Chemother Pharmacol. Internet]. 2013;72:1223–1234. Available from. http://link.springer.com/10.1007/s00280-013-2287-6
- CENTER FOR DRUG EVALUATION AND RESEARCH. Clinical pharmacology and biopharmaceutics review (211349Orig1s000). gilteritinib (xospata). Food Drug Adm. Internet]. 2018; Available from. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211349Orig1s000MultidisciplineR.pdf
- Ouatas T, Duval V, Sinclair K, et al. Concomitant use of midostaurin with strong CYP3A4 inhibitors: an analysis from the ratify trial. Blood. 2017;130:3814.
- Sugiyama M, Fujita K, Murayama N, et al. Sorafenib and sunitinib, two anticancer drugs, inhibit CYP3A4-mediated and activate CY3A5-mediated midazolam 1’-hydroxylation. Drug Metab Dispos. 2011;39:757–762.
- Schlafer D. Management of midostaurin-CYP3A4 drug-drug interactions in patients with acute myeloid leukemia. In: Vose JM, Davidson NE, Janjan M, editors. Oncology (Williston Park). 2019. p. 33.
- Tollkuci E. Isavuconazole therapy in an FLT3 mutated acute myeloid leukemia patient receiving midostaurin: a case report. J Oncol Pharm Pract Internet]. 2019;25:987–989. Available from. http://journals.sagepub.com/doi/10.1177/1078155218764257
- Schlenk RF, Fiedler W, Salih HR, et al. Impact of age and midostaurin-dose on response and outcome in acute myeloid leukemia with FLT3-ITD: interim-analyses of the AMLSG 16-10 trial. Blood Internet]. 2016;128:449. Available from. https://ashpublications.org/blood/article/128/22/449/101354/Impact-of-Age-and-MidostaurinDose-on-Response-and
- Schlenk RF, Weber D, Fiedler W, et al. Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD. Blood Internet]. 2019;133:840–851. Available from.;.:https://ashpublications.org/blood/article/133/8/840/260612/Midostaurin-added-to-chemotherapy-and-continued
- Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. Internet]. 2017;377:454–464. Available from. http://www.nejm.org/doi/10.1056/NEJMoa1614359
- Tisdale JE. Drug-induced QT interval prolongation and torsades de pointes. Can Pharm J/Rev Des Pharm du Canada. Internet]. 2016 [cited 2020 Mar 18];149:139–152. Available from;:.:http://journals.sagepub.com/doi/10.1177/1715163516641136
- European Medicines Agency (EMA). Bristol-myers squibb pharma. Vidaza (azacitidina): EU prescribing information; 2013.
- Williams CB, Kambhampati S, Fiskus W, et al. Preclinical and phase i results of decitabine in combination with midostaurin (PKC412) for newly diagnosed elderly or relapsed/refractory adult patients with acute myeloid leukemia. Pharmacother J Hum Pharmacol Drug Ther. Internet]. 2013;33:1341–1352. Available from. https://onlinelibrary.wiley.com/doi/10.1002/phar.1316
- Cooper BW, Kindwall-Keller TL, Craig MD, et al. A phase i study of midostaurin and azacitidine in relapsed and elderly AML patients. Clin Lymphoma Myeloma Leuk Internet]. 2015;15:428–432.e2. Available from. https://linkinghub.elsevier.com/retrieve/pii/S2152265015000464
- Roboz GJ, Strickland SA, Litzow MR, et al. Updated safety of midostaurin plus chemotherapy in newly diagnosed FLT3 mutation–positive acute myeloid leukemia: the RADIUS-X expanded access program. Leuk Lymphoma. Internet]. 2020;61:3146–3153. Available from. https://www.tandfonline.com/doi/full/10.1080/10428194.2020.1805109
- U.S. Food and Drug Administration (FDA). Astellas pharma (2018) xospata (gilteritinib): US prescribing information. 2018; Available from: https://www.accessdata.fda.gov/%0Adrugsatfda_docs/label/2018/211349s000lbl.pdf.
- Levis M, Smith C, Litzow M, et al. Drug-drug interaction potential of gilteritinib in healthy subjects and patients with relapsed/refractory acute myeloid leukemia. Haematol Conf 22th Congr Eur Hematol Assoc Spain, Madrid (Spain) [Internet]. 2017;102:386.Availablefrom: https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01399260/full.
- Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3 -mutated AML. N Engl J Med. Internet]. 2019;381:1728–1740. Available from. http://www.nejm.org/doi/10.1056/NEJMoa1902688
- Wang ES, Montesinos P, Minden MD, et al. Phase 3, open-label, randomized study of gilteritinib and azacitidine vs azacitidine for newly diagnosed FLT3 -mutated acute myeloid leukemia in patients ineligible for intensive induction chemotherapy. Blood Internet]. 2021;138:700. Available from. https://ashpublications.org/blood/article/138/Supplement.1/700/479521/Phase-3-Open-Label-Randomized-Study-of.
- Tzogani K, Røshol H, Olsen HH, et al. The European medicines agency review of gilteritinib (xospata) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an flt3 mutation. Oncologist Internet]. 2020;25:e1070–e1076. Available from. https://academic.oup.com/oncolo/article/25/7/e1070/6443390
- Li J, Kankam M, Trone D, et al. Effects of CYP3A inhibitors on the pharmacokinetics of quizartinib, a potent and selective FLT3 inhibitor, and its active metabolite. Br J Clin Pharmacol. Internet]. 2019;85:2108–2117. Available from. https://onlinelibrary.wiley.com/doi/abs/10.1111/bcp.14022
- Comitte for Medicinal Products from Human Use (CHMP). European Public Assessment Resport (EPAR) - quizartinib (vanflyta) EMEA/H/C/004468/0000. 2019; Available from: https://www.ema.europa.eu/en/documents/assessment-report/vanflyta-epar-refusal-public-assessment-report_en.pdf.
- Li J, Kumar P, Anreddy N, et al. Quizartinib (AC220) reverses ABCG2-mediated multidrug resistance: in vitro and in vivo studies. Oncotarget. Internet]. 2017;8:93785–93799. Available from. http://www.oncotarget.com/fulltext/21078
- Bhullar J, Natarajan K, Shukla S, et al. The FLT3 inhibitor quizartinib inhibits ABCG2 at pharmacologically relevant concentrations, with implications for both chemosensitization and adverse drug interactions. Szakacs G. ed. PLoS One. Internet]. 2013;8:e71266. Available from. https://dx.plos.org/10.1371/journal.pone.0071266
- Li J, Trone D, Mendell J, et al. A drug–drug interaction study to assess the potential effect of acid-reducing agent, lansoprazole, on quizartinib pharmacokinetics. Cancer Chemother Pharmacol. 2019;84:799–807. Internet
- U.S. Food and Drug Administration (FDA). Oncology Drug Advisory Committee. Briefing document for the May 14, 2019 YS FDA Oncology Drugs. Quizartinib NDA 212166. FDA Advis Comm Brief Doc. Internet]. 2019;NDA 212166. Available from.https://www.fda.gov/media/125640/download
- Cortes JE, Kantarjian H, Foran JM, et al. Phase I Study of Quizartinib Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FMS-Like Tyrosine Kinase 3–Internal Tandem Duplication Status. J Clin Oncol. Internet]. 2013;31:3681–3687. Available from. http://ascopubs.org/doi/10.1200/JCO.2013.48.8783
- Cortes JE, Tallman MS, Schiller GJ, et al. Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD–mutated, relapsed or refractory AML. Blood. 2018;132:598–607. Internet. Available from. https://ashpublications.org/blood/article/132/6/598/39411/Phase-2b-study-of-2-dosing-regimens-of-quizartinib
- Cortes JE, Khaled S, Martinelli G, et al. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol Internet]. 2019;20:984–997. Available from. https://linkinghub.elsevier.com/retrieve/pii/S1470204519301500
- Swaminathan M, Kantarjian HM, Levis M, et al. A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Haematologica Internet]. 2021; Available from. 106;2121–2130.:https://haematologica.org/article/view/haematol.2020.263392
- Kang D, Ludwig E, Jaworowicz D, et al. Concentration–QTc analysis of quizartinib in patients with relapsed/refractory acute myeloid leukemia. Cancer Chemother Pharmacol. 2021;87:513–523. Internet
- European Medicines Agency (EMA). Bayer Pharmaceutical Division (2020) Nexavar (sorafenib): EU prescribing information. 2020; Available from: https://www.ema.europa.eu/en/documents/product-information/nexavar-epar-product-information_en.pdf.
- van Erp NP, Gelderblom H, Guchelaar HJ. Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. Internet]. 2009;35:692–706.
- Grandinetti CA, Goldspiel BR. Sorafenib and sunitinib: novel targeted therapies for renal cell cancer. Pharmacotherapy Internet]. 2007;27:1125–1144
- Truong DH, Tran TH, Ramasamy T, et al. Preparation and characterization of solid dispersion using a novel amphiphilic copolymer to enhance dissolution and oral bioavailability of sorafenib. Powder Technol Internet]. 2015;283:260–265. Available from. https://linkinghub.elsevier.com/retrieve/pii/S0032591015003290
- Thomas-Schoemann A, Blanchet B, Bardin C, et al. Drug interactions with solid tumour-targeted therapies. Crit Rev Oncol Hematol. 2014;89:179–196. Internet
- Hu S, Chen Z, Franke R, et al. Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res. Internet]. 2009;15:6062–6069. Available from. http://clincancerres.aacrjournals.org/lookup/doi/10.1158/1078-0432.CCR-09-0048
- Rimassa L, Danesi R, Pressiani T, et al. Management of adverse events associated with tyrosine kinase inhibitors: improving outcomes for patients with hepatocellular carcinoma. Cancer Treat Rev. 2019;77:20–28. Internet
- Gomo C, Coriat R, Faivre L, et al. Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma. Invest New Drugs. Internet]. 2011;29:1511–1514. Available from. http://link.springer.com/10.1007/s10637-010-9514-3
- Takahara T, Nitta H, Hasegawa Y, et al. Using sorafenib for recurrent hepatocellular Carcinoma after liver transplantation-interactions between calcineurin inhibitor: two case reports. Transplant Proc. 2011;43:2800–2805. Internet
- Vasilyeva A, Durmus S, Li L, et al. Hepatocellular shuttling and recirculation of sorafenib-glucuronide is dependent on abcc2, Abcc3, and Oatp1a/1b. Cancer Res. Internet]. 2015;75:2729–2736. Available from. http://cancerres.aacrjournals.org/lookup/doi/10.1158/0008-5472.CAN-15-0280
- Bins S, van Doorn L, Phelps M, et al. Influence of OATP1B1 function on the disposition of sorafenib-β-D-glucuronide. Clin Transl Sci. Internet]. 2017;10:271–279. Available from. https://onlinelibrary.wiley.com/doi/10.1111/cts.12458
- Duckett DR, Cameron MD. Metabolism considerations for kinase inhibitors in cancer treatment. Expert Opin Drug Metab Toxicol Internet]. 2010;6:1175–1193. Available from.;:. http://www.tandfonline.com/doi/full/10.1517/17425255.2010.506873
- Mazard T, Causse A, Simony J, et al. Sorafenib overcomes irinotecan resistance in colorectal cancer by inhibiting the ABCG2 drug-efflux pump. Mol Cancer Ther. Internet]. 2013;12:2121–2134. Available from. http://mct.aacrjournals.org/lookup/doi/10.1158/1535-7163.MCT-12-0966
- Terada T, Noda S, Inui KI. Management of dose variability and side effects for individualized cancer pharmacotherapy with tyrosine kinase inhibitors. Pharmacol Ther. 2015;152:125–134. Internet
- Zhang L, Wu F, Lee SC, et al. pH-dependent drug-drug interactions for weak base drugs: potential implications for new drug development. Clin Pharmacol Ther. 2014;96:266–277.
- Razak RA, Fletcher P, Kunene V, et al. Association of gastric acid suppression and sorafenib efficacy in advanced hepatocellular carcinoma. J Clin Gastroenterol. 2021;55:169–173.
- Noda S, Shioya M, Hira D, et al. Pharmacokinetic interaction between sorafenib and prednisolone in a patient with hepatocellular carcinoma. Cancer Chemother Pharmacol. 2013;72:269–272.
- Comitte for Medicinal Products from Human Use (CHMP). SCIENTIFIC DISCUSSION - sorafenib (nexavar) EMEA/H/C/690/II/05. 2007; Available from: https://www.ema.europa.eu/en/documents/scientific-discussion-variation/nexavar-h-c-690-ii-05-epar-scientific-discussion-variation_en.pdf.
- Comitte for Medicinal Products from Human Use (CHMP). European public assessment resport (EPAR) - sorafenib (nexavar) EMEA/H/C/000690/II/0035. 2014; Available from: https://www.ema.europa.eu/en/documents/variation-report/nexavar-h-c-690-ii-35-epar-assessment-report-variation_en.pdf.
- Asari K, Takahashi H. Prediction of the impact of CYP2C9 and VKORC1 genotypes on warfarin–sorafenib interactions in whites and Asians. Pharmacogenomics Internet. 2020;21:853–862. Available from.;:. https://www.futuremedicine.com/doi/10.2217/pgs-2020-0036
- Wang Z, Xiang X, Liu S, et al. A physiologically based pharmacokinetic/pharmacodynamic modeling approach for drug-drug interaction evaluation of warfarin enantiomers with sorafenib. Drug Metab Pharmacokinet. 2021;39:100362. Internet
- Moretti LV, Montalvo RO. Elevated international normalized ratio associated with concurrent use of sorafenib and warfarin. Am J Heal Pharm. 2009;66:2123–2125.
- Lathia C, Lettieri J, Cihon F, et al. Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics. Cancer Chemother Pharmacol. Internet]. 2006;57:685–692. Available from. http://link.springer.com/10.1007/s00280-005-0068-6
- Lindsay J, Teh BW, Micklethwaite K, et al. Azole antifungals and new targeted therapies for hematological malignancy. Curr Opin Infect Dis. 2019;32:538–545.
- Takimoto CH, Awada A. Safety and anti-tumor activity of sorafenib (Nexavar®) in combination with other anti-cancer agents: a review of clinical trials. Cancer Chemother Pharmacol. 2008;61:535–548.
- Egron A, Olivier-Abbal P, Gouraud A, et al. Preventable and potentially preventable serious adverse reactions induced by oral protein kinase inhibitors through a database of adverse drug reaction reports. Target Oncol. Internet]. 2015;10:229–234. Available from. http://link.springer.com/10.1007/s11523-014-0328-7
- Kloth JSL, Pagani A, Verboom MC, et al. Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors. Br J Cancer Internet]. 2015;112:1011–1016. Available from. http://www.nature.com/articles/bjc201582
- Tolcher AW, Appleman LJ, Shapiro GI, et al. A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer. Cancer Chemother Pharmacol. Internet]. 2011;67:751–764. Available from. http://link.springer.com/10.1007/s00280-010-1372-3
- Ohanian M, Garcia-Manero G, Levis M, et al. Sorafenib combined with 5-azacytidine in older patients with untreated FLT3 -ITD mutated acute myeloid leukemia. Am J Hematol. Internet]. 2018;93:1136–1141. Available from. https://onlinelibrary.wiley.com/doi/10.1002/ajh.25198
- Ravandi F, Cortes JE, Jones D, et al. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol. Internet]. 2010;28:1856–1862. Available from. https://ascopubs.org/doi/10.1200/JCO.2009.25.4888
- Comitte for Medicinal Products from Human Use (CHMP). European Public Assessment Resport (EPAR) - ponatinib (iclusig) EMEA/H/C/002695/0000. 2013;
- European Medicines Agency (EMA). Incyte biosciences distribution B.V. Iclusig (ponatinib): EU prescribing information; 2015.
- Ye YE, Woodward CN, Narasimhan NI. Absorption, metabolism, and excretion of [14C]ponatinib after a single oral dose in humans. Cancer Chemother Pharmacol Internet]. 2017;79:507–518. Available from. http://link.springer.com/10.1007/s00280-017-3240-x
- Narasimhan NI, Dorer DJ, Niland K, et al. Effects of food on the pharmacokinetics of ponatinib in healthy subjects. J Clin Pharm Ther. 2013;38:440–444.
- Lu L, Saunders VA, Leclercq TM, et al. Ponatinib is not transported by ABCB1, ABCG2 or OCT- 1 in CML cells. Leukemia Internet]. 2015;29:1792–1794. Available from. http://www.nature.com/articles/leu201535
- Maia R, Vasconcelos F, Souza P, et al. Towards comprehension of the ABCB1/P-glycoprotein role in chronic myeloid leukemia. Molecules Internet. 2018;23:119.Availablefrom. http://www.mdpi.com/1420-3049/23/1/119
- Sen R, Natarajan K, Bhullar J, et al. The novel BCR-ABL and FLT3 inhibitor ponatinib Is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2. Mol Cancer Ther. Internet]. 2012;11:2033–2044. Available from. http://mct.aacrjournals.org/lookup/doi/10.1158/1535-7163.MCT-12-0302
- Sun Y-L, Kumar P, Sodani K, et al. Ponatinib enhances anticancer drug sensitivity in MRP7-overexpressing cells. Oncol Rep. Internet]. 2014;31:1605–1612. Available from. https://www.spandidos-publications.com/10.3892/or.2014.3002
- Beretta GL, Cassinelli G, Pennati M, et al. Overcoming ABC transporter-mediated multidrug resistance: the dual role of tyrosine kinase inhibitors as multitargeting agents. Eur J Med Chem. Internet]. 2017;142:271–289.
- Narasimhan NI, Dorer DJ, Davis J, et al. Evaluation of the effect of multiple doses of lansoprazole on the pharmacokinetics and safety of ponatinib in healthy subjects. Clin Drug Investig. Internet. 2014;34:723–729. Available from. http://link.springer.com/10.1007/s40261-014-0225-y
- Narasimhan NI, Dorer DJ, Niland K, et al. Effects of ketoconazole on the pharmacokinetics of ponatinib in healthy subjects. J Clin Pharmacol. Internet]. 2013;53:974–981. Available from. https://onlinelibrary.wiley.com/doi/10.1002/jcph.109
- Narasimhan NI, Dorer DJ, Davis J, et al. Evaluation of the effect of multiple doses of rifampin on the pharmacokinetics and safety of ponatinib in healthy subjects. Clin Pharmacol Drug Dev. Internet]. 2015;4:354–360. Available from. https://onlinelibrary.wiley.com/doi/10.1002/cpdd.182
- Sonnichsen D, Dorer DJ, Cortes J, et al. Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies. Cancer Chemother Pharmacol. Internet. 2013;71:1599–1607. Available from. http://link.springer.com/10.1007/s00280-013-2160-7
- Cortes J, Apperley J, Lomaia E, et al. Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial. Blood Internet]. 2021;138:2042–2050. Available from. https://ashpublications.org/blood/article/138/21/2042/476603/Ponatinib-dose-ranging-study-in-chronic-phase
- Zimmerman EI, Turner DC, Buaboonnam J, et al. Crenolanib is active against models of drug-resistant FLT3-ITD−positive acute myeloid leukemia. Blood Internet]. 2013;122:3607–3615. Available from. https://ashpublications.org/blood/article/122/22/3607/31974/Crenolanib-is-active-against-models-of
- Panetta JC, Baker SD, Kantarjian HM, et al. Population pharmacokinetics of crenolanib, a type I FLT3 inhibitor, in patients with relapsed/refractory AML. Blood Internet]. 2015 [cited 2022 Feb 15];126:3695. Available from. https://ash.confex.com/ash/2015/webprogramscheduler/Paper83493.html
- NHS. Crenolanib for advanced or metastatic gastrointestinal stromal tumours (GISTs) with the D842V mutation in the PDGFRA gene. UK: National System of Health. 2018. p. 1–11.
- Mathias TJ, Natarajan K, Shukla S, et al. The FLT3 and PDGFR inhibitor crenolanib is a substrate of the multidrug resistance protein ABCB1 but does not inhibit transport function at pharmacologically relevant concentrations. Invest New Drugs. Internet]. 2015;33:300–309. Available from. http://link.springer.com/10.1007/s10637-015-0205-y
- TF P, GR T, DW D, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America. Clin Infect Dis Internet]. 2016;63:e1–e60. Available from. https://academic.oup.com/cid/article/63/4/e1/2595039
- Rodríguez-Veiga R, Montesinos P, Boluda B, et al. Incidence and outcome of invasive fungal disease after front-line intensive chemotherapy in patients with acute myeloid leukemia: impact of antifungal prophylaxis. Ann Hematol. Internet]. 2019;98:2081–2088. Available from. http://link.springer.com/10.1007/s00277-019-03744-5
- Weis TM, Marini BL, Bixby DL, et al. Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia. Crit Rev Oncol Hematol. 2019;141:125–138. Internet
- Greco R, Lorentino F, Albanese S, et al. Posttransplantation cyclophosphamide- and sirolimus-based graft-versus-host-disease prophylaxis in allogeneic stem cell transplant. Transplant Cell Ther Internet]. 2021;27:776.e1–776.e13. Available from https://linkinghub.elsevier.com/retrieve/pii/S2666636721009428